Last reviewed · How we verify
Encequidar tablet
Encequidar is a potent and selective inhibitor of P-glycoprotein.
Encequidar is a potent and selective inhibitor of P-glycoprotein. Used for Treatment of cancer, particularly in combination with chemotherapeutic agents.
At a glance
| Generic name | Encequidar tablet |
|---|---|
| Sponsor | Health Hope Pharma |
| Drug class | P-glycoprotein inhibitor |
| Target | P-glycoprotein |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting P-glycoprotein, Encequidar increases the bioavailability of co-administered chemotherapeutic agents, thereby enhancing their therapeutic efficacy. This mechanism is particularly relevant in the context of cancer treatment, where P-glycoprotein can act as a barrier to drug entry into cancer cells.
Approved indications
- Treatment of cancer, particularly in combination with chemotherapeutic agents
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |